|
|
|
| Research progress of T cell subsets in the process of pulmonary fibrosis |
| QIAN Mengdan1 MA Ningyi2 WANG Yan1 LI Ya3 |
1.The First School of Clinical Medicine, Henan University of Chinese Medicine, Henan Province, Zhengzhou 450046, China;
2.Collaborative Innovation Center for the Prevention and Treatment of Respiratory Diseases in Chinese Medicine, Henan University of Chinese Medicine, Henan Province, Zhengzhou 450046, China;
3.Traditional Chinese Medicine Pharmacology (Respiratory) Laboratory, the First Affiliated Hospital of Henan University of Chinese Medicine, Henan Province, Zhengzhou 450000, China
|
|
|
|
Abstract Pulmonary fibrosis is a chronic interstitial disease characterized by changes in lung tissue structure, and idiopathic pulmonary fibrosis is the most serious one. The etiology of idiopathic pulmonary fibrosis is unknown and the pathogenesis is complex, with T lymphocyte-dominated immune inflammation playing a key role in the lung fibrosis process. T cells are classified into different subpopulations according to their different pathways in immune inflammation: Th cells, Treg cells, Tc cells, and NKT cells. Different T lymphocyte subsets and cytokines mediated by them are highly expressed in pulmonary fibrosis, which can regulate immune injury and inflammatory reaction in pulmonary fibrosis by releasing or inhibiting inflammatory cytokines, and then affect the degree of lung tissue injury, collagen secretion and myofibroblast proliferation, so as to participate in the process of pulmonary fibrosis. In this article, the different pathological responses of T cell subsets and their induced cytokines in the process of pulmonary fibrosis are reviewed, and the mechanisms of their action in the process of pulmonary fibrosis is discussed, which could provide a deeper direction for the clinical treatment and basic research of pulmonary fibrosis.
|
|
|
|
|
|
[1] Piotrowski WJ，Bestry I，Bialas AJ，et al. Guidelines of the polish respiratory society for diagnosis and treatment of idiopathic pulmonary fibrosis [J]. Adv Respir Med，2020，88（1）：41-93.
[2] Kropski JA，Blackwell TS. Progress in understanding and trea- ting idiopathic pulmonary fibrosis [J]. Annu Rev Med，2019， 70：211-224.
[3] Yamazaki R，Nishiyama O，Yoshikawa K，et al. Clinical course and prognosis in survivors of acute exacerbations of idiopathic pulmonary fibrosis [J]. Respir Investig，2021，59（4）：408- 413.
[4] Gulati S，Thannickal VJ. The aging lung and idiopathic pulmonary fibrosis [J]. Am J Med Sci，2019，357（5）：384-389.
[5] Glass DS，Grossfeld D，Renna H A，et al. Idiopathic pulmonary fibrosis：current and future treatment [J]. Clin Respir J，2022， 16（2）：84-96.
[6] 李星，朱振华，吴仲敏，等.PPARγ激活剂对博莱霉素诱导小鼠肺纤维化的改善作用[J].中华全科医学，2021，19（9）：1455-1458.
[7] 蔡欣，李炎玉，苏国媚，等.膜联蛋白A1促进肺成纤维细胞炎症反应及胶原合成的研究[J].中华全科医学，2021， 19（11）：1807-1810.
[8] Moss BJ，Ryter SW，Rosas IO. Pathogenic mechanisms underlying idiopathic pulmonary fibrosis [J]. Annu Rev Pathol，2022，17：515-546.
[9] Heukels P，Moor CC，von der Thusen JH，et al. Inflammation and immunity in IPF pathogenesis and treatment [J]. Respir Med，2019，147：79-91.
[10] Shenderov K，Collins SL，Powell JD，et al. Immune dysregulation as a driver of idiopathic pulmonary fibrosis [J]. JClin Invest，2021，131（2）：e143226.
[11] Jee AS，Sahhar J，Youssef P，et al. Review：serum biomarkers in idiopathic pulmonary fibrosis and systemic sclerosis associated interstitial lung disease-frontiers and horizons [J]. Pharmacol Ther，2019，202：40-52.
[12] 曾珠，王飞，张巍，等.补阳还五汤联合黄芩素对肺纤维化大鼠炎性因子表达的影响研究[J].中国临床药理学杂志，2020，36（1）：29-31.
[13] 邢琳琳，国建飞，阮昕，等.丹参川芎嗪联合泼尼松治疗肺间质纤维化[J].长春中医药大学学报，2019，35（3）：464-467.
[14] 朱德伟，沈云辉.积雪草苷对平阳霉素诱导的大、小鼠肺纤维化的保护作用[J].上海中医药大学学报，2020， 34（6）：41-46.
[15] Judd J，Dulaimi E，Li T，et al. Low level of blood CD4+ T cells is an independent predictor of inferior progression-free survival in diffuse large B-cell lymphoma [J]. Clin Lymphoma Myeloma Leuk，2017，17（2）：83-88.
[16] Yanagihara T，Sato S，Upagupta C，et al. What have we learned from basic science studies on idiopathic pulmonary fibrosis? [J]. Eur Respir Rev，2019，28（153）：190029.
[17] Singh B，Kasam RK，Sontake V，et al. Repetitive intradermal bleomycin injections evoke T-helper cell 2 cytokine- driven pulmonary fibrosis [J]. Am J Physiol Lung Cell Mol Physiol，2017，313（5）：L796-L806.
[18] Yombo D，Odayar V，Gupta N，et al. The protective effects of IL-31RA deficiency during bleomycin-induced pulmonary fibrosis [J]. Front Immunol，2021，12：645717.
[19] 毛雪丽，张娜，赵鹏飞，等.细胞因子对肺纤维化的影响及机制研究进展[J].临床肺科杂志，2020，25（5）：778- 781.
[20] 杨丽，吕晓东，刘妍彤，等.参龙煎剂干预肺纤维化大鼠血清IFN-γ、IL-4表达水平影响的实验研究[J].中华中医药学刊，2017，35（6）：1427-1430.
[21] Deng Y，Wang Z，Chang C，et al. Th9 cells and IL-9 in autoimmune disorders：pathogenesis and therapeutic potentials [J]. Hum Immunol，2017，78（2）：120-128.
[22] Deng KM，Yang XS，Luo Q，et al. Deleterious role of Th9 cells in pulmonary fibrosis [J]. Cells，2021，10（11）：3209.
[23] Overed-Sayer C，Rapley L，Mustelin T，et al. Are mast cells instrumental for fibrotic diseases? [J]. Front Pharmacol，2014， 4：174.
[24] Noelle RJ，Nowak EC. Cellular sources and immune functions of interleukin-9 [J]. Nat Rev Immunol，2010，10（10）：683-687.
[25] Weng D，Chen XQ，Qiu H，et al. The role of infection in acute exacerbation of idiopathic pulmonary fibrosis [J]. Mediators Inflamm，2019，2019：5160694.
[26] Sugimoto N，Suzukawa M，Nagase H，et al. IL-9 blockade suppresses silica-induced lung inflammation and fibrosis in mice [J]. Am J Respir Cell Mol Biol，2019，60（2）：232-243.
[27] Zhu S，Qian Y. IL-17/IL-17 receptor system in autoimmune disease：mechanisms and therapeutic potential [J]. Clin Sci（Lond），2012，122（11）：487-511.
[28] Desai O，Winkler J，Minasyan M，et al. The role of immune and inflammatory cells in idiopathic pulmonary fibrosis [J]. Front Med（Lausanne），2018，5：43.
[29] Cong LH，Li T，Wang H，et al. IL-17A-producing T cells exacerbate fine particulate matter-induced lung inflammation and fibrosis by inhibiting PI3K/Akt/mTOR-mediated autophagy [J]. J Cell Mol Med，2020，24（15）：8532-8544.
[30] Wang F，Xia H，Yao S. Regulatory T cells are a double- edged sword in pulmonary fibrosis [J]. Int Immunopharmacol，2020，84：106443.
[31] Zhang JH，Deng JH，Yao XL，et al. CD4+CD25+ Tregs as dep- endent factor in the course of bleomycin-induced pulmonary fibrosis in mice [J]. Exp Cell Res，2020，386（1）：111700.
[32] Wang B，Bai W，Ma H，et al. Regulatory effect of PD1/ PD-Ligand 1（PD-L1） on Treg cells in patients with idiopa- thic pulmonary fibrosis [J]. Med Sci Monit，2021，27：e927577.
[33] Garibaldi BT，D’Alessio FR，Mock JR，et al. Regulatory T cells reduce acute lung injury fibroproliferation by decreasing fibrocyte recruitment [J]. Am J Respir Cell Mol Biol，2013，48（1）：35-43.
[34] Chakraborty K，Chatterjee S，Bhattacharyya A. Impact of Treg on other T cell subsets in progression of fibrosis in experimental lung fibrosis [J]. Tissue Cell，2018，53：87-92.
[35] Seyran M，Melanie S，Philip S，et al. Allies or enemies? The effect of regulatory T cells and related T lymphocytes on the profibrotic environment in bleomycin-injured lung mouse models [J]. Clin Exp Med，2023，23（4）：1075-1088.
[36] Sivori S，Pende D，Quatrini L，et al. NK cells and ILCs in tumor immunotherapy [J]. Mol Aspects Med，2021，80：100870.
[37] Celada LJ，Kropski JA，Herazo-Maya JD，et al. PD-1 up- regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-beta1 production [J]. Sci Transl Med，2018，10（460）：eaar8356.
[38] Shimizu K，Iyoda T，Yamasaki S，et al. NK and NKT cell- mediated immune surveillance against hematological malignancies [J]. Cancers（Basel），2020，12（4）：817.
[39] Godfrey DI，Le Nours J，Andrews DM，et al. Unconventional T cell targets for cancer immunotherapy [J]. Immunity，2018，48（3）：453-473.
[40] Zhang M，Zhang S. T cells in fibrosis and fibrotic diseases [J]. Front Immunol，2020，11：1142.
[41] Arora S，Thompson PJ，Wang Y，et al. Invariant natural killer T cells coordinate removal of senescent cells [J]. Med，2021， 2（8）：938-950. |
|
|
|
